Smoking Cessation Drugs Get Boxed Warning
Evans, Jeff, Clinical Psychiatry News
Accumulating reports of serious neuropsychiatric symptoms associated with the smoking cessation medications varenicline and bupropion have prompted the Food and Drug Administration to require new boxed warnings for the drugs.
The warnings, which went into effect July 1. highlight symptoms that include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and suicide.
The manufacturers also are required to revise the plain-language medication guides that come with the drugs.
The requirements will affect the drugs that are specifically indicated for smoking cessation--Chantix (varenicline), manufactured by Pfizer Inc., and …
The rest of this article is only available to active members of Questia
Sign up now for a free, 1-day trial and receive full access to:
- Questia's entire collection
- Automatic bibliography creation
- More helpful research tools like notes, citations, and highlights
- Ad-free environment
Already a member? Log in now.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information:
Article title: Smoking Cessation Drugs Get Boxed Warning.
Contributors: Evans, Jeff - Author.
Magazine title: Clinical Psychiatry News.
Volume: 37.
Issue: 8
Publication date: August 2009.
Page number: 4.
© 2009 International Medical News Group.
COPYRIGHT 2009 Gale Group.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.
One moment ...
- Georgia
- Arial
- Times New Roman
- Verdana
- Courier/monospaced
Reset